利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

88 条记录 (耗时 0.026 秒)

    Sub-tenon drug delivery
    43.
    发明授权
    Sub-tenon drug delivery 有权
    子腱药物递送

    公开(公告)号：US06413245B1

    公开(公告)日：2002-07-02

    申请号：US09677656

    申请日：2000-10-04

    申请人： Yoseph Yaacobi ,  Abbot F. Clark ,  David C. Dahlin ,  Craig B. Struble ,  David Allen Marsh ,  Billie M. York

    发明人： Yoseph Yaacobi ,  Abbot F. Clark ,  David C. Dahlin ,  Craig B. Struble ,  David Allen Marsh ,  Billie M. York

    IPC分类号： A61M2500

    CPC分类号： A61F9/0017 ,  A61F2250/0067

    摘要： Disclosed is a method and apparatus for delivering a drug formulation to a human eye. The method includes the steps of inserting the apparatus below the Tenon's capsule and above the sclera at a point posterior to the limbus of the eye and injecting the drug formulation to form a drug depot on an outer surface of the sclera. The apparatus includes a cannula having a distal portion, a proximal portion, and a bend separating the distal portion and the proximal portion. The distal portion has a radius of curvature substantially equal to a radius of curvature of the globe of the eye. A tangent of the distal portion at the bend is disposed at an angle no more than about 56 degrees with respect to the proximal portion.

    摘要翻译： 公开了用于将药物制剂递送至人眼的方法和装置。 该方法包括以下步骤：将装置插入Tenon's胶囊下方并在巩膜上方的眼睛边缘后方注射药物制剂以在巩膜的外表面上形成药物贮库。 该装置包括具有远侧部分，近端部分和分离远侧部分和近端部分的弯曲部的套管。 远端部分的曲率半径基本上等于眼睛球体的曲率半径。 弯曲处的远侧部分的切线相对于近端部分以不超过约56度的角度设置。

    Ophthalmic composition
    44.
    发明授权
    Ophthalmic composition 失效
    眼科成分

    公开(公告)号：US5407926A

    公开(公告)日：1995-04-18

    申请号：US966118

    申请日：1992-10-23

    申请人： Abbot F. Clark

    发明人： Abbot F. Clark

    IPC分类号： A61K31/565 ,  A61K31/57 ,  A61K31/58 ,  A61K31/665 ,  C07J3/00 ,  C07J5/00 ,  C07J9/00 ,  C07J11/00 ,  C07J41/00 ,  C07J51/00 ,  A61K31/56

    CPC分类号： A61K31/569 ,  A61K31/565 ,  A61K31/57 ,  A61K31/573 ,  A61K31/58 ,  A61K31/665 ,  C07J11/00 ,  C07J3/00 ,  C07J41/0005 ,  C07J41/0027 ,  C07J5/0053 ,  C07J51/00 ,  C07J9/00

    摘要： Pharmaceutical compositions useful in the treatment of ophthalmic inflammation and methods of treating ophthalmic inflammation with those compositions are disclosed. The compositions contain a combination of a glucocorticoid and an angiostatic steroid. The angiostatic steroid substantially prevents any significant increases in intraocular pressure which might otherwise be experienced by the patient as a side effect of the glucocorticoid component of the compositions. The therapeutic interaction of the two components therefore allows the potent anti-inflammatory properties of the glucocorticoids to be utilized without fear of elevating intraocular pressure.

    摘要翻译： 公开了可用于治疗眼部炎症的药物组合物和用这些组合物治疗眼部炎症的方法。 组合物含有糖皮质激素和血管抑制类固醇的组合。 血管抑制类固醇基本上防止了眼睛压力的任何显着增加，否则患者可能会经历该组合物的糖皮质激素成分的副作用。 因此，两种组分的治疗相互作用允许使用糖皮质激素的有效抗炎特性，而不用担心升高眼内压。

    Use of tetrahydrocortisol to prevent elevations in intraocular pressure caused by corticosteroids
    45.
    发明授权
    Use of tetrahydrocortisol to prevent elevations in intraocular pressure caused by corticosteroids 失效
    使用四氢皮质醇来防止由皮质类固醇引起的眼压升高

    公开(公告)号：US5358943A

    公开(公告)日：1994-10-25

    申请号：US12181

    申请日：1993-02-02

    申请人： Abbot F. Clark ,  Aaron L. Southren

    发明人： Abbot F. Clark ,  Aaron L. Southren

    IPC分类号： A61K31/57 ,  A61K31/56 ,  A61K31/33

    CPC分类号： A61K31/57 ,  Y10S514/914 ,  Y10S514/922

    摘要： Pharmaceutical compositions useful in the treatment of ophthalmic inflammation and methods of treating ophthalmic inflammation with those compositions are disclosed. The compositions contain a combination of a glucocorticoid and tetrahydrocortisol. The tetrahydrocortisol serves to substantially prevent any significant increases in intraocular pressure which might otherwise be experienced by the patient as a side effect of the glucocorticoid component of the compositions. The therapeutic interaction of the two components therefore allows the potent antiinflammatory properties of the glucocorticoids to be utilized without fear of elevating intraocular pressure. A method of preventing increases in intraocular pressure attributable to systemic or topical corticosteroid therapy is also disclosed. That method involves the administration of a pharmaceutical composition containing tetrahydrocortisol to a patient receiving such therapy.

    摘要翻译： 公开了可用于治疗眼部炎症的药物组合物和用这些组合物治疗眼部炎症的方法。 组合物含有糖皮质激素和四氢皮质醇的组合。 四氢皮质醇用于基本上防止眼睛压力的任何显着增加，否则患者可能会经历该组合物的糖皮质激素成分的副作用。 因此，两种组分的治疗相互作用允许使用糖皮质激素的有效的抗炎特性，而不用担心升高眼内压。 还公开了防止全身或局部皮质类固醇治疗引起的眼压升高的方法。 该方法涉及向接受这种治疗的患者施用含有四氢皮质醇的药物组合物。

    Use of tetrahydrocortexolone to prevent elevations in intraocular pressure caused by corticosteroids
    46.
    发明授权
    Use of tetrahydrocortexolone to prevent elevations in intraocular pressure caused by corticosteroids 失效
    使用四氢胆固醇来防止由皮质类固醇引起的眼压升高

    公开(公告)号：US4945089A

    公开(公告)日：1990-07-31

    申请号：US399351

    申请日：1989-08-28

    申请人： Abbot F. Clark

    发明人： Abbot F. Clark

    IPC分类号： A61K31/57

    CPC分类号： A61K31/57

    摘要： Pharmaceutical compositions useful in the treatment of ophthalmic inflammation and methods of treating ophthalmic inflammation with those compositions are disclosed. The compositions contain a combination of a glucocorticoid and tetrahydrocortexolone. The tetrahydrocortexolone serves to substantially prevent any significant increases in intraocular pressure which might otherwise by experienced by the patient as a side effect of the glucocorticoid component of the compositions. The therapeutic interaction of the two components therefore allows the potent antiinflammatory properties of the glucocorticoids to be utilized without fear of elevating intraocular pressure. A method of preventing increases in intraocular pressure attributable to systemic or topical corticosteroid therapy is also disclosed. That method involves the administration of a pharmaceutical composition containing tetrahydrocortexolone to a patient receiving such therapy.

    摘要翻译： 公开了可用于治疗眼部炎症的药物组合物和用这些组合物治疗眼部炎症的方法。 组合物含有糖皮质激素和四氢胆固醇的组合。 四氢胆固醇用于基本上防止眼内压的任何显着增加，否则可能由患者经受的作为组合物的糖皮质激素成分的副作用。 因此，两种组分的治疗相互作用允许使用糖皮质激素的有效的抗炎特性，而不用担心升高眼内压。 还公开了防止全身或局部皮质类固醇治疗引起的眼压升高的方法。 该方法涉及向接受这种治疗的患者施用含有四氢胆固醇的药物组合物。